Jazz Pharmaceuticals Plc Stock Today
| JAZZ Stock | USD 138.76 1.81 1.29% |
PerformanceOK
| Odds Of DistressLow
|
Jazz Pharmaceuticals is trading at 138.76 as of the 23rd of March 2025; that is 1.29 percent decrease since the beginning of the trading day. The stock's open price was 140.57. Jazz Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of June 2007 | Category Healthcare | Classification Health Care |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland. The company has 60.73 M outstanding shares of which 4.53 M shares are currently shorted by private and institutional investors with about 4.96 trading days to cover. More on Jazz Pharmaceuticals PLC
Moving together with Jazz Stock
Moving against Jazz Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Jazz Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Bruce Cozadd | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsJazz Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Jazz Pharmaceuticals' financial leverage. It provides some insight into what part of Jazz Pharmaceuticals' total assets is financed by creditors.
| |||||
Jazz Pharmaceuticals PLC (JAZZ) is traded on NASDAQ Exchange in USA. It is located in Waterloo Exchange, Dublin, Ireland, D04 E5W7 and employs 2,800 people. Jazz Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.43 B. Jazz Pharmaceuticals PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 60.73 M outstanding shares of which 4.53 M shares are currently shorted by private and institutional investors with about 4.96 trading days to cover.
Jazz Pharmaceuticals PLC currently holds about 899.36 M in cash with 1.4 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28.
Check Jazz Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationJazz Pharmaceuticals PLC has a total of 60.73 Million outstanding shares. The majority of Jazz Pharmaceuticals PLC outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jazz Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jazz Pharmaceuticals PLC. Please pay attention to any change in the institutional holdings of Jazz Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Also note that almost one million eight hundred fifteen thousand nine hundred two invesors are currently shorting Jazz Pharmaceuticals expressing very little confidence in its future performance.
Check Jazz Ownership Details
Jazz Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 1.1 M | |
| Polaris Capital Management, Llc | 2024-12-31 | 1.1 M | |
| Swedbank Ab | 2024-12-31 | 1 M | |
| Renaissance Technologies Corp | 2024-12-31 | 1 M | |
| Vestal Point Capital Lp | 2024-12-31 | 975 K | |
| Fuller & Thaler Asset Management Inc | 2024-12-31 | 939.4 K | |
| Fmr Inc | 2024-12-31 | 742.3 K | |
| Thompson, Siegel & Walmsley Llc | 2024-12-31 | 700.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 661 K | |
| Vanguard Group Inc | 2024-12-31 | 6 M | |
| Blackrock Inc | 2024-12-31 | 5.9 M |
Jazz Pharmaceuticals Historical Income Statement
Jazz Stock Against Markets
Jazz Pharmaceuticals Corporate Management
| Finbar Larkin | VP Operations | Profile | |
| George Eliades | Senior Officer | Profile | |
| Daniel Swisher | NonExecutive Employee | Profile | |
| Jeff Macdonald | Executive Relations | Profile | |
| Patricia Carr | Senior Officer | Profile | |
| Jed MD | Senior Medicine | Profile |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.